Digexin Study Shows Butyrate-Forward Microbiome Modulation Without Fiber or Live Biotics

A new ex vivo study evaluating NXT USA’s Digexin ingredient found that it promotes butyrate-forward microbial fermentation, a key marker of gut health, without relying on traditional fibers or live biotics, positioning the botanical extract as a microbiome modulator.¹

Conducted independently by ProDigest² using validated human colon simulation models, the research demonstrated that Digexin actively engages the gut microbiome to support beneficial metabolic activity while avoiding undesirable byproducts typically associated with proteolytic fermentation. The findings suggest a distinct mechanism of action compared to conventional prebiotics, which rely on fiber fermentation to drive microbial changes.

What Did the Study Reveal About Digexin’s Microbiome Activity?

According to the study, Digexin drove a selective, butyrate-focused fermentation profile, increasing short-chain fatty acid (SCFA) production, particularly butyrate, which is widely associated with intestinal barrier integrity, immune signaling, and digestive comfort. The ingredient also demonstrated coordinated microbial cross-feeding, beginning with lactate production followed by downstream utilization, a hallmark of a balanced microbial ecosystem.

“We already know Digexin delivers real relief for people dealing with irregular bowel movements, bloating, gas, and especially constipation,” said Eric Anderson, NXT USA’s managing director. “This study helps explain why—showing that Digexin engages the gut microbiome in a way that promotes butyrate-forward fermentation and balanced microbial metabolism. It reinforces Digexin’s multi-pathway approach to digestive health, without relying on fibers or live bacteria.”

Digexin did not stimulate proteolytic fermentation pathways, which are often linked to gastrointestinal discomfort and harmful metabolites. Instead, microbial activity remained aligned with carbohydrate-driven pathways, reinforcing what the company describes as a “high-quality” fermentation response.

Shifts in microbial composition further supported these findings, with increased abundance of taxa associated with SCFA production and improved metabolic function.

How Was the Research Conducted?

The study utilized ProDigest’s SHIME (Simulator of the Human Intestinal Microbial Ecosystem) model, followed by its Kinetic Colon-on-a-Plate system, which simulates human colonic fermentation under physiologically relevant conditions. While ex vivo, these models are widely used in ingredient development to generate mechanistic insights prior to human trials.

NXT USA noted that the findings, though yet to be published, are intended to inform future clinical research, with additional studies underway exploring inflammation and gut barrier integrity.

How Does Digexin Differ From Traditional Prebiotics?

Unlike conventional prebiotics, which are typically fermentable fibers, Digexin appears to modulate the microbiome environment rather than directly feeding bacteria, according to Todd Runestad, chief storytelling officer at NXT USA.

“Digexin is functionally a prebiotic but structurally not a fiber that ferments like traditional prebiotics,” he mentioned to Nutritional Outlook. “It does not feed bacteria like prebiotics, but it changes the environment bacteria live in. Digexin is a microbiome + motility modulator. … Call Digexin a unicorn. It’s a microbiome and motility modulator that delivers prebiotic-like outcomes without relying on fiber or live bacteria.”

This distinction could be significant for formulators seeking alternatives to fiber-heavy products or probiotic-based solutions, particularly as stability, dosing, and consumer tolerance remain ongoing challenges in those categories.

What Does This Mean for Product Development?

For finished product manufacturers, Digexin’s positioning as a non-fiber, non-biotic microbiome ingredient could offer formulation flexibility across categories such as digestive health, active nutrition, and even stress-related gut support.

The ingredient, a proprietary extraction of okra and ashwagandha, has already been associated with benefits including relief from bloating, gas, and irregular bowel movements, according to the company. The new data provides a potential mechanistic explanation for these outcomes, linking them to microbiome-mediated effects rather than direct laxation or fiber bulking.

As consumer demand grows for multi-functional, evidence-backed digestive health solutions, ingredients that can deliver targeted microbiome modulation without traditional limitations may gain traction.

References

1. New research positions Digexin as a next-generation, prebiotic-like microbiome modulator. NXT USA. April 29, 2026. Accessed May 4, 2026. Press release delivered via email.

2. ProDigest official website. ProDigest. Accessed May 4, 2026. https://prodigest.eu/